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• Refractory vasodilatory shock develops from uncontrolled 
vasodilation and hyporesponsiveness to vasopressors.
• Management of calcium channel blockers (CCB) toxicity can be 
difficult because it can result in refractory vasodilatory shock 
making it often fatal despite standard treatment. 
• 21-year-old male with history of depression and prior suicide 
attempts presented after intentional ingestion of amlodipine 
(300 mg) and metformin (150 tablets of 1000 mg). 
• Presented with slightly altered mentation and hypotension, then 
quickly deteriorated and required intubation and high 
vasopressor requirements. 
• Transferred to PSVMC for consideration of venoarterial
extracorporeal membrane oxygenation (VA-ECMO). Since he was 
hyperdynamic on echocardiogram, our team did not feel he 
would benefit from VA-ECMO.  
• His vasopressor requirements surpassed the normal 
recommended doses
• Due to no improvement, methylene blue and 
hydroxycobalamine (vitamin B12) were initiated for his refractory 
shock.
• He responded favorably to this therapy. Norepinephrine dose 
was halved and Epinephrine down to 10 mcg/min almost 
immediately. 
• It took several days to wean him off the vasopressors and he was 
able to transfer to the medical floor in stable condition. 
• Higher doses of vasopressors are typically required for CCB toxicity and co-
ingestions can also alter the pharmacokinetics in unpredictable ways.
• Emerging therapies, such as methylene blue and vitamin B12, were tried. These 
have previously been used in cardiac patients who experienced vasoplegia
postoperatively. 
• Methylene blue and vitamin B12 are thought to increase systemic vascular 
resistance by decreasing  nitric oxide synthesis thereby preventing smooth muscle 
relaxation allowing vasoconstriction in response to catecholamines (Figure 1).
• Both therapies have been used only in case-series and case-reports; there has yet 
to be randomized trials to validate their use.  
• Interesting side effect of methylene blue and vitamin B12 depicted in Figure 2 & 3. 
This resulted in his urine turing purple. The CRRT sensor needed to be changed so 
that the machine did not think his urine was blood.
• This case highlights the importance of considering alternative therapies such as 
methylene blue and vitamin B12 in cases of refractory shock unresponsive to 
standard therapies. 
Figure 1: Mechanism of methylene blue: Cytokines and ROS 
upregulate nitric oxide synthase and stimulates soluble 
guanylate cyclase (sGC), both of which generate cGMP. cGMP 
shifts calcium into the sarcoplasmic reticulum (SR) therefore 
lowering intracellular calcium concentration and decreasing 
contraction. Methylene blue inhibits both NO synthesis and 
cGMP synthesis
Figure 2 & 3: Methylene blue turns 
urine green blue and vitamin B12 turns 
urine red
Patient Normal
Norepinephrine 200 mcg/min 30 mcg/min
Epinephrine 100 mcg/min 5-20 mcg/min
Phenylephrine 360 mcg/min 5-200 mcg min
Vasopressin 0.04 U/min 0.01-0.04 U/min
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